Core Insights - Phibro Animal Health Corporation has entered into a licensing agreement with Lighthouse Pharmaceuticals for a novel therapeutic asset aimed at periodontal health in companion animals [1] - The agreement provides Phibro with exclusive rights to develop, manufacture, and commercialize Lighthouse Pharma's proprietary compound specifically for canine periodontal care [1] - The compound is described as promising, indicating potential for significant impact in the animal health market [1]